公开(公告)号：US20100047787A1

公开(公告)日：2010-02-25

申请号：US12391224

申请日：2009-02-23

Applicant: Xiao-Jun Ma ,  Chin-Lee Wu ,  Mark G. Erlander ,  William Scott McDougal

Inventor： Xiao-Jun Ma ,  Chin-Lee Wu ,  Mark G. Erlander ,  William Scott McDougal

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158

Abstract: The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to prostate cancer. In particular, the disclosure is based on the identities of genes that are correlated with patient survival and prostate cancer recurrence. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats and used to predict the survival of subjects afflicted with prostate cancer and to predict prostate cancer recurrence. The profiles may also be used in the study and/or diagnosis of prostate cancer cells and tissue as well as for the study and/or determination of prognosis of a patient. When used for diagnosis or prognosis, the profiles may be used to determine the treatment of prostate cancer based upon probable life expectancy and cancer recurrence and/or metastasis.

Abstract translation: 该公开内容包括鉴定和使用与前列腺癌临床相关的基因表达谱或模式。 特别地，本公开内容基于与患者存活和前列腺癌复发相关的基因的身份。 基因表达谱可以体现在核酸表达，蛋白质表达或其他表达形式中，并用于预测患有前列腺癌的受试者的存活并预测前列腺癌复发。 该谱也可用于研究和/或诊断前列腺癌细胞和组织，以及用于研究和/或确定患者的预后。 当用于诊断或预后时，可根据可能的预期寿命和癌症复发和/或转移来确定前列腺癌的治疗方法。

公开(公告)号：US20070020655A1

公开(公告)日：2007-01-25

申请号：US11422056

申请日：2006-06-02

Applicant: Mark Erlander ,  Xiao-Jun Ma

Inventor： Mark Erlander ,  Xiao-Jun Ma

IPC: C12Q1/68 ,  G06F19/00

CPC classification number: G16B40/00 ,  C12Q1/6886 ,  C12Q2600/112 ,  G16B25/00

Abstract: The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.

Abstract translation: 本发明提供了使用基因表达测量法在临床环境中从受试者获得的样品中分类或鉴定肿瘤的方法，例如在福尔马林固定的石蜡包埋（FFPE）样品的情况下。

公开(公告)号：US20060263806A1

公开(公告)日：2006-11-23

申请号：US11381353

申请日：2006-05-02

Applicant: Xiao-Jun Ma ,  Dennis Sgroi ,  Mark Erlander

Inventor： Xiao-Jun Ma ,  Dennis Sgroi ,  Mark Erlander

IPC: C12Q1/68 ,  G06F19/00

CPC classification number: G01N33/57496 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/154 ,  C12Q2600/158 ,  G01N33/57415

Abstract: Methods and compositions are provided for the detection of breast cancer based upon the identification of three biomarkers for non-normal breast cells. The biomarkers were identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer. Two biomarkers display increased expression in non-normal cells while the third biomarker displays decreased expression in non-normal cells.

Abstract translation: 基于鉴定非正常乳腺细胞的三种生物标志物，提供了用于检测乳腺癌的方法和组合物。 基于来自独立乳腺癌病例的参考乳腺组织样品的多次取样来鉴定生物标志物。 两个生物标志物在非正常细胞中显示出增加的表达，而第三个生物标志物在非正常细胞中显示出降低的表达。

公开(公告)号：US20060088851A1

公开(公告)日：2006-04-27

申请号：US11145061

申请日：2005-06-03

Applicant: Mark Erlander ,  Dennis Sgroi ,  Xiao-Jun Ma

Inventor： Mark Erlander ,  Dennis Sgroi ,  Xiao-Jun Ma

IPC: C12Q1/68 ,  G01N33/574

CPC classification number: C12Q1/6827 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/154

Abstract: This invention relates to the detection of increased expression from the HoxB13 (homeobox B13) gene as indicative of an invasive or metastatic cancer phenotype. The invention provides methods of detecting the level of expression from the HoxB13 gene, optionally in combination with nodal status, as an indicator of the invasive or metastatic phenotype as well as increased cellular migration and/or mobility. The invention also provides for the measurement of expression from the HoxB13 gene to assist in the determination of patient prognosis as well as clinical diagnosis and treatment.

Abstract translation: 本发明涉及从HoxB13（同源盒B13）基因增加的表达的检测，指示侵袭性或转移性癌症表型。 本发明提供了检测来自HoxB13基因的表达水平的方法，任选地与结节状态组合，作为侵袭性或转移表型的指标以及增加的细胞迁移和/或迁移率。 本发明还提供了来自HoxB13基因的表达的测量以帮助确定患者的预后以及临床诊断和治疗。

公开(公告)号：US20050239079A1

公开(公告)日：2005-10-27

申请号：US10727100

申请日：2003-12-02

Applicant: Mark Erlander ,  Xiao-Jun Ma ,  Dennis Sgroi

Inventor： Mark Erlander ,  Xiao-Jun Ma ,  Dennis Sgroi

IPC: C12M1/34 ,  C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/154 ,  C12Q2600/158

Abstract: Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to tamoxifen treatment. The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with ER+ breast cancer with tamoxifen. Additional methods and compositions are provided for predicting tamoxifen responsiveness in cases of ER+ breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.

Abstract translation: 提供方法和组合物用于鉴定ER +乳腺癌病例中的表达标志，其中签名与他莫昔芬治疗的反应性或缺乏相关。 基于来自乳腺癌独立病例的参考乳腺组织样本的抽样来鉴定特征谱，并提供可靠的一组分子标准，用于预测使用他莫昔芬治疗患有ER +乳腺癌的受试者的功效。 提供了另外的方法和组合物，用于通过使用三种生物标志物来预测ER +乳腺癌患者中的他莫昔芬反应性。 两种生物标志物显示与他莫昔芬反应相关的增加的表达，而第三种生物标志物显示与他莫昔芬反应相关的降低的表达。